Clinical Trial Update: A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A 104-week Phase 3 trial comparing long-term glycemic control of IDegLira versus insulin glargine in adults with type 2 diabetes; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• IDegLira (insulin degludec/liraglutide)
• Insulin Glargine (insulin glargine)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2019-11-27